Even after its passage in 2024, the investor and mathematician billionaire Jim Simons is still known as the “King How much” in coverage funds due to the extraordinary success of Renaissance technologiesYour quantitative negotiation company based in New York. After years of financial industry research, Simons realized the potential without exploiting quantitative analyzes to take advantage of market inefficiencies. This vision led him to develop an investment strategy based on data to analyze market behavior only through statistical and mathematical models. By identifying the subtle patterns and not random in financial data, the genius as much predicted future movements of the actions and generated impressive returns.
Although closed to external investors, the secret fund of the medallion of Jim Simons, a Renaissance flagship, has produced innovative results since its inception. The Medallion Fund gained impressive returns of 56.6% and 74.6% during the first Dot-Compe accident in the early 2000’s and the world financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $ 31.4 billion, placing it among the richest individuals in the world, thanks to the strong performance of the Market Market Medallion and Renaissance.
The Renaissance Technologies computer based power plant began to begin after stellar realization in 2024. The Renaissance diversified Alpha Fund 11.85% in the first two months of 2025. Both funds can maintain important positions of individual stock, as well as use future actions index and options to help manage the risk. However, the firm warns that it may be difficult to quickly undo these important stakes without affecting market prices.
For this list, we have chosen actions of the Renaissance Technologies 13f portfolio in the late quarter of 2024. These actions are also popular with elite coverage funds.
Why are we interested in the stocks that cover the funds? The reason is simple: our research has shown that we can overcome the market by imitating the best stock options for the best coverage funds. The strategy of our quarterly bulletin selects 14 stocks of small layers and large layers each quarter and has returned 373.4% since May 2014, surpassing its reference point at 218 percentage points (Check out more details here)).
Gilead Sciences, Inc. (GILD) Is the best stock to buy according to Jim Simons Renaissance technologies?
A doctor and a patient who have a discussion in a hospital on biopharmaceutical medicines.
Renaissance Q4 Technologies Estaca: $ 492.3 million
Number of coverage fund holders: 74
Gilead Sciences, Inc. (NASDAQ: GILD), an American biopharmaceutical company based in Foster City, California, focuses on developing antiviral treatments for diseases such as Covid-19, Hepatitis B and C, influence and HIV/AIDS.
During the first quarter of 2025, Gilead Sciences, Inc. (NASDAQ: GILD) reported total sales of $ 6.6 billion products, a decrease in 1% year -on -year. Although Covid-19 Treatment Sales decreased, the company’s base business, excluding Veklury, grew 4% year-on-year to $ 6.3 billion, indicating the underlying force of its main portfolio. HIV products remained the main point of Gilead’s operations, representing sales of $ 4.6 billion (70% of total income) and increasing 6% year -on -year.
On May 7, Gilead Sciences, Inc. (NASDAQ: GILD) announced that it would invest additional $ 11 billion in the United States to strengthen its national manufacturing and research abilities, becoming one of the last companies to reveal spending plans in response to President Donald Trump’s fare policy. According to the pharmaceutical company, the new investments will increase a budget of $ 21 billion already reserved to support the North -American and R&D manufacturing until 2030. These expenses will be assigned to update three existing locations, build three new facilities and acquire new technologies.
Clearbridge value strategy indicated the following on Gilead Sciences, Inc. (NASDAQ: GILD) In its first quarter 2025 Investor letter:
“Health care actions populated our best performers for the quarter. Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) announced a strong growth in the fourth quarter gains, and the news was also raised that its HIV Lenacapavir prevention medicine had been presented for the United States approval, with a scheduled launch planned for mid -2015, and in a positive reception in its cirrhosis of Livdelzi liver treatment in the first complete quarter. “”
Usually golden Rankes 10th In our list of best shares to buy according to Renaissance technologies by Jim Simons. Although we recognize Gild’s potential as an investment, our conviction lies in the belief that some AI actions have a greater promise to obtain higher yields and do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for a stock of Ia more promising than GILD but sells less than five times, see our report on this Ia stock cheap.
